Company
Immix
Create medicines that work without destroying the person.
Also known as Immix Biopharma, Immix Biopharma, Inc., ImmixBio
- Business model
- B2B
- Headquarters
- Los Angeles, CA, United States
- Legal name
- Immix Biopharma, Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation.
Funding snapshot
- Total raised
- $150MSum of rounds, as of 2026-09-19Source (opens in a new tab)
- Latest round
- Secondary, $150M2026-05-21
Funding rounds
- Secondary
- $150M2026-05-21, Company stated
- Round, 2024
- 2024-05-2014 investors
Products
- Other
- NXC-201
- Web
- NXC-201
Loading relationship preview